In the treatment of COVID-19, ivermectin use is associated with decreased mortality compared to remdesivir use, according to a study published in the International Journal of Infectious Diseases. Researchers at the University of Miami retrospectively analyzed a national federated database of adults 18 years old and above with a recorded COVID-19 infection between January 2020 and July 2021. They compared those who used ivermectin but not remdesivir with those who used remdesivir but not ivermectin. Variables that may have effected COVID-19 survival outcomes were controlled, including “age, gender, race, ethnicity, nicotine use diabetes mellitus, obesity, chronic lower respiratory disease, ischemic heart diseases, tocilizumab, glucocorticoids, or ventilator use.” “After using propensity score matching and adjusting for potential confounders, ivermectin was associated with reduced mortality vs remdesivir,” researchers reported. “To our knowledge, this is the largest association study of patients with COVID-19, mortality and ivermectin.” The risk difference was reported at -5.224 …